Sponsors (8)
The bill trades faster, clearer, and broader federal control of a class of dangerous synthetic opioids — which may reduce illicit supply and ease enforcement — against tighter restrictions that threaten research and clinical access, increase risks of criminalization for trace exposures, and weaken procedural safeguards for rulemaking.
People at risk of opioid overdose and their communities may see reduced illicit availability of dangerous nitazene-related opioids, which could lower overdose harms.
Law enforcement can more easily prosecute and interdict a broad class of potent synthetic opioids because the bill permanently controls and criminalizes those substances.
The Attorney General / DEA can publish a Federal Register list that gives clearer notice about which substances are controlled, helping clinicians, clinical labs, and researchers know the legal status of specific compounds.
Scientists and clinicians face tighter restrictions, licensing and paperwork to study, synthesize, or handle the covered compounds, which will likely slow scientific research into these substances.
Patients with opioid use disorder or those who might benefit from investigational therapies could lose access to treatment or clinical research options if related compounds become unavailable.
People possessing trace amounts (including in mixtures or contaminants) of newly defined compounds could face criminal penalties because the definition covers 'any quantity' and many salt/isomer forms unless specifically exempted.
Based on analysis of 6 sections of legislative text.
Permanently places nitazene-class 2-benzylbenzimidazole opioids into Schedule I, allows AG to list related compounds, and requires implementing rules within one year.
Introduced March 18, 2026 by Robert E. Latta · Last progress March 18, 2026
Adds a broad class of nitazene-related 2-benzylbenzimidazole opioids to Schedule I of the Controlled Substances Act, makes any substances temporarily emergency-scheduled under existing authority permanently Schedule I as of enactment, and directs the Attorney General to issue implementing rules within one year (allowing interim final rules that take immediate effect but still permit public comment and hearings). It defines the covered class both by chemical structure and by mu-opioid receptor activity, lists specific named substances, and authorizes the Attorney General to publish and update a Federal Register list of covered compounds.